These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 15058160

  • 1. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K.
    Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J, Arkosy P, Lenkey A, Sápy P.
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [Abstract] [Full Text] [Related]

  • 5. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Jun; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 6. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.
    Sperti C, Pasquali C, Guolo P, Polverosi R, Liessi G, Pedrazzoli S.
    Cancer; 1996 Jul 15; 78(2):237-43. PubMed ID: 8673998
    [Abstract] [Full Text] [Related]

  • 7. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
    Nouts A, Lévy P, Voitot H, Bernades P.
    Gastroenterol Clin Biol; 1998 Feb 15; 22(2):152-9. PubMed ID: 9762189
    [Abstract] [Full Text] [Related]

  • 8. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F, Roscher R, Beger HG.
    Hepatogastroenterology; 1989 Dec 15; 36(6):419-23. PubMed ID: 2613165
    [Abstract] [Full Text] [Related]

  • 9. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
    Cwik G, Wallner G, Skoczylas T, Krzyzanowski M, Ciechainski A, Madro P.
    Ann Univ Mariae Curie Sklodowska Med; 2004 Dec 15; 59(2):213-8. PubMed ID: 16146081
    [Abstract] [Full Text] [Related]

  • 10. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Dec 15; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 11. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 Dec 15; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

  • 12. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A, Evangelista A, Mariani A, Bersani M, Bonato C, Basilico M, Montorsi M, Beretta E.
    Int J Pancreatol; 1988 Dec 15; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [Abstract] [Full Text] [Related]

  • 13. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.
    Gastroenterol Hepatol; 1999 Dec 15; 22(7):335-41. PubMed ID: 10535205
    [Abstract] [Full Text] [Related]

  • 14. [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
    Dai MH, Zhao YP, Cai LX, Zhu Y.
    Zhonghua Wai Ke Za Zhi; 2003 May 15; 41(5):332-5. PubMed ID: 12892584
    [Abstract] [Full Text] [Related]

  • 15. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.
    Pancreas; 2007 May 15; 34(4):436-43. PubMed ID: 17446843
    [Abstract] [Full Text] [Related]

  • 16. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
    Liao WC, Wu MS, Wang HP, Tien YW, Lin JT.
    Pancreas; 2009 May 15; 38(4):422-6. PubMed ID: 19214136
    [Abstract] [Full Text] [Related]

  • 17. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR.
    J Surg Res; 2007 Jun 01; 140(1):31-5. PubMed ID: 17418869
    [Abstract] [Full Text] [Related]

  • 18. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.
    Clin Cancer Res; 2006 Jan 15; 12(2):442-6. PubMed ID: 16428484
    [Abstract] [Full Text] [Related]

  • 19. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
    Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM.
    J Clin Oncol; 2006 Jan 10; 24(2):252-8. PubMed ID: 16344318
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic mucinous cyst adenocarcinoma producing CA 19-9. A case report.
    Ishigami S, Baba K, Mataki Y, Noma H, Maemura K, Shinchi H, Takao S, Natsugoe S, Aikou T.
    JOP; 2007 Mar 10; 8(2):228-31. PubMed ID: 17356248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.